LYSINE
Metastatic Neuroendocrine Prostate Cancer
Novartis PharmaceuticalsSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Metastatic Neuroendocrine Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxodotreotide Novartis Pharmaceuticals | Phase 2 | B |
VIPIVOTIDE TETRAXETAN Novartis Pharmaceuticals | Phase 1 | CC |
Psma-Hbed-Cc Novartis Pharmaceuticals | Phase 1 | CC |
Bl-M14D1 SystImmune Inc. | Phase 1 | CC |
ARG Novartis Pharmaceuticals | Phase 1 | CC |
DOTA-PABZA-DIG-DPHE-GLN-TRP-ALA-VAL-GLY-HIS-NHCH(CH2CH(CH3)2)2 Novartis Pharmaceuticals | Phase 1 | CC |
METOCLOPRAMIDE Novartis Pharmaceuticals | Phase 1 | CC |
Same molecule, other indications
LYSINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →